



**Subject:** Wigs\*

**Effective Date:** March 27, 2007

**Department:** Utilization Management

---

**Policy:** Wigs (considered to be a DME cranial prosthesis appliance) are reimbursable under plans administered by QualCare, Inc.

**Objective:** To assure proper and consistent reimbursement and to delineate criteria that provides evidence of medical necessity for a specific type of DME.

**Procedure:**

A. In the absence of a specific provision in the individual Summary Plan Description (SPD), wigs (**HCPCS A9282**) are reimbursable, up to dollar limits in individual SPDs, for hair loss caused by the following:

1. Burns (**ICD-9 941**) (**ICD 10-T20.05XA, T20.09XA, T20.30XA, T20.35XA, T20.45XA, T20.49XA, T20.70XA, T20.75XA, T26.40XA, T26.41XA, T20.42XA** )
2. Cancer chemotherapy (**999.8**) (**ICD 10- Z92.21**)
3. Radiation therapy (**990**) (**ICD 10- Z92.3**)

4. Congenital baldness (757.4) (ICD 10- Q84.0, Q84.1, Q84.2 )
5. Infections resulting in permanent hair loss that is unresponsive to treatment (704.09) ( ICD 10- L63.0, L63.1, L65.9,L66.8 )
6. Lupus and other connective tissue diseases (710) (ICD 10- M32.0, M32.10, M32.19, M32.8, M32.9)
7. Traumatic injury (906) (ICD 10- S01.00XS-S01.05XS,S00.00XS-S00.07XS, S07.1XXs, T20.05XS)

B. Wigs are not reimbursable for any of the following, as for these conditions they are considered not medically necessary:

1. Male pattern baldness (704.00) ( ICD 10- L64.9, L65.9)
2. Female pattern baldness (704.00) (ICD 10- L64.9, L65.9 )
3. Natural aging process (704.00) ( ICD 10- L64.9, L65.9 )
4. Damage to existing wig secondary to color dying or other wig treatment
5. Cosmetic purposes

References:

Park J, Kim JI, Yun SK, Kim HU, Ihm CW. Pattern Alopecia during Hormonal Anticancer Therapy in Patients with Breast Cancer. *Ann Dermatol.* 2014;26(6):743-6(Dec)

Emslie C, Whyte F, Campbell A, *et al.* ‘I wouldn’t have been interested in just sitting round a table talking about cancer’; exploring the experience of women with breast cancer’; exploring the experience of women with breast cancer in a group exercise trial. *Health Educ Res* 2007; 22(6): 827-838(Dec)

American Cancer Society. Hair loss. Updated 2003 Mar. Available at: [http://www.cancer.org/docroot/MBC/content/MBC\\_2\\_3X\\_Hair\\_Loss.asp?sitearea=MBC](http://www.cancer.org/docroot/MBC/content/MBC_2_3X_Hair_Loss.asp?sitearea=MBC) Accessed Jan 21, 2005.

Rosman S. Cancer and stigma: Experience of patients with chemotherapy-induced alopecia. *Patient Educ Couns* 2004;52(3):333-339 (Mar)

Harrison S, Sinclair R. Optimal management of hair loss (alopecia) in children. *Am J Dermatol* 2003;4(11):717-770 (Nov)

Botchkarev V. Molecular mechanisms of chemotherapy-induced hair loss. *J Investig Dermatol Symp Proc.* 2003;8(Suppl 1):72-5 (Jun).

McGarvey E, Baum L, Pinkerton R, Rogers L. Psychological sequelae and alopecia among women with cancer. *Cancer Pract* 2001;9(6):283-9 (Nov-Dec)

Williams J, Wood C, Cunningham-Warburton P. A narrative study of chemotherapy-induced alopecia. *Oncol Nurs Forum* 1999;26(9):1463-1468 (Oct)

Moore KA. Breast cancer patients' out-of-pocket expenses. *Cancer Nurs* 1999;22(5):389-396 (Oct)

Sommer M, Wilson C. Therapeutic approaches to the management of common baldness. *Int J Clin Pract* 1999;53(56):381-385 (Jul-Aug)

Ahmad W, ul Haque MF, Brancolini V, Tsou H, ul Haque S, Lam H, et al. Alopecia universalis associated with a mutation in the human hairless gene. *Science* 1998;279(5351):720-724 (Jan 30)

Dorr VJ. A practitioner's guide to cancer-related alopecia. *Semin Oncol* 1998;25(5):562-570 (Oct)

Pappas PG, Kauffman CA, Perfect J, et al. Alopecia associated with fluconazole therapy. *Ann Intern Med* 1995;123(5):354-357 (Sep 1)

Drafted By: Mark S. Cukierman, M.D.  
Approved By/Date: QMCommittee/03/27/07  
Revised By/Date: BFisher, MD 10/01/09  
Approved By/Date: QM Committee 10/27/09  
Reviewed w/o Revision By/Date: MMcNeil, MD 11/21/11  
Approved By/Date: QM Committee 12/13/11  
Revised By/Date: MMcNeil, MD 05/04/15  
Approved by/Date: QM Committee, 05/19/15  
Reviewed w/o revision By/Date: MMcNeil, 9/28/17  
Approved By/Date: QMC, 10/17/17

\*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.